559 related articles for article (PubMed ID: 31926856)
1. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
2. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
5. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
6. Heart failure with preserved ejection fraction phenogroup classification using machine learning.
Kyodo A; Kanaoka K; Keshi A; Nogi M; Nogi K; Ishihara S; Kamon D; Hashimoto Y; Nakada Y; Ueda T; Seno A; Nishida T; Onoue K; Soeda T; Kawakami R; Watanabe M; Nagai T; Anzai T; Saito Y
ESC Heart Fail; 2023 Jun; 10(3):2019-2030. PubMed ID: 37051638
[TBL] [Abstract][Full Text] [Related]
7. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
9. The HFA-PEFF score identifies 'early-HFpEF' phenogroups associated with distinct biomarker profiles.
Henkens MTHM; van Ommen AM; Remmelzwaal S; Valstar GB; Wang P; Verdonschot JAJ; Hazebroek MR; Hofstra L; van Empel VPM; Beulens JWJ; den Ruijter HM; Heymans SRB
ESC Heart Fail; 2022 Jun; 9(3):2032-2036. PubMed ID: 35301820
[TBL] [Abstract][Full Text] [Related]
10. Characteristics, prognosis and treatment response in distinct phenogroups of heart failure with preserved ejection fraction.
Gu J; Pan JA; Lin H; Zhang JF; Wang CQ
Int J Cardiol; 2021 Jan; 323():148-154. PubMed ID: 32860842
[TBL] [Abstract][Full Text] [Related]
11. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
12. Deep-Learning Models for the Echocardiographic Assessment of Diastolic Dysfunction.
Pandey A; Kagiyama N; Yanamala N; Segar MW; Cho JS; Tokodi M; Sengupta PP
JACC Cardiovasc Imaging; 2021 Oct; 14(10):1887-1900. PubMed ID: 34023263
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
[TBL] [Abstract][Full Text] [Related]
14. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.
Segar MW; Patel KV; Ayers C; Basit M; Tang WHW; Willett D; Berry J; Grodin JL; Pandey A
Eur J Heart Fail; 2020 Jan; 22(1):148-158. PubMed ID: 31637815
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
[TBL] [Abstract][Full Text] [Related]
16. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
[TBL] [Abstract][Full Text] [Related]
18. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
[TBL] [Abstract][Full Text] [Related]
19. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
20. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
